FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004240693> ?p ?o ?g. }

• W2004240693 endingPage "e89612" @default.
• W2004240693 startingPage "e89612" @default.
• W2004240693 abstract "Objectives To evaluate the safety, tolerability and immunogenicity of three different doses (5, 25 and 50 µg) of the novel antituberculous vaccine RUTI compared to placebo in subjects with latent tuberculosis infection. Methods and Findings Double-blind, randomized, placebo-controlled Phase II Clinical Trial (95 patients randomized). Three different RUTI doses and placebo were tested, randomized both in HIV-positive (n = 47) and HIV-negative subjects (n = 48), after completion of one month isoniazid (INH) pre-vaccination. Each subject received two vaccine administrations, 28 Days apart. Five patients withdrew and 90 patients completed the study. Assessment of safety showed no deaths during study. Two subjects had serious adverse events one had a retinal detachment while taking INH and was not randomized and the other had a severe local injection site abscess on each arm and was hospitalized; causality was assessed as very likely and by the end of the study the outcome had resolved. All the patients except 5 (21%) patients of the placebo group (3 HIV+ and 2 HIV−) reported at least one adverse event (AE) during the study. The most frequently occurring AEs among RUTI recipients were (% in HIV+/−): injection site reactions [erythema (91/92), induration (94/92), local nodules (46/25), local pain (66/75), sterile abscess (6/6), swelling (74/83), ulcer (20/11), headache (17/22) and nasopharyngitis (20/5)]. These events were mostly mild and well tolerated. Overall, a polyantigenic response was observed, which differed by HIV− status. The best polyantigenic response was obtained when administrating 25 µg RUTI, especially in HIV-positive subjects which was not increased after the second inoculation. Conclusion This Phase II clinical trial demonstrates reasonable tolerability of RUTI. The immunogenicity profile of RUTI vaccine in LTBI subjects, even being variable among groups, allows us considering one single injection of one of the highest doses in future trials, preceded by an extended safety clinical phase. Trial Registration ClinicalTrials.gov NCT01136161" @default.
• W2004240693 created "2016-06-24" @default.
• W2004240693 creator A5000283880 @default.
• W2004240693 creator A5022654117 @default.
• W2004240693 creator A5025743822 @default.
• W2004240693 creator A5033082495 @default.
• W2004240693 creator A5038820719 @default.
• W2004240693 creator A5047058016 @default.
• W2004240693 creator A5073149554 @default.
• W2004240693 creator A5081226931 @default.
• W2004240693 creator A5091914061 @default.
• W2004240693 date "2014-02-26" @default.
• W2004240693 modified "2023-10-06" @default.
• W2004240693 title "Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection" @default.
• W2004240693 cites W1977575192 @default.
• W2004240693 cites W1983763479 @default.
• W2004240693 cites W2008284948 @default.
• W2004240693 cites W2009517518 @default.
• W2004240693 cites W2012125828 @default.
• W2004240693 cites W2021321915 @default.
• W2004240693 cites W2025328459 @default.
• W2004240693 cites W2035288424 @default.
• W2004240693 cites W2060352709 @default.
• W2004240693 cites W2063986522 @default.
• W2004240693 cites W2079757735 @default.
• W2004240693 cites W2083602561 @default.
• W2004240693 cites W2083701335 @default.
• W2004240693 cites W2100897644 @default.
• W2004240693 cites W2143296217 @default.
• W2004240693 cites W2163625719 @default.
• W2004240693 cites W2164794843 @default.
• W2004240693 cites W2170209192 @default.
• W2004240693 doi "https://doi.org/10.1371/journal.pone.0089612" @default.
• W2004240693 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3935928" @default.
• W2004240693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24586912" @default.
• W2004240693 hasPublicationYear "2014" @default.
• W2004240693 type Work @default.
• W2004240693 sameAs 2004240693 @default.
• W2004240693 citedByCount "92" @default.
• W2004240693 countsByYear W20042406932014 @default.
• W2004240693 countsByYear W20042406932015 @default.
• W2004240693 countsByYear W20042406932016 @default.
• W2004240693 countsByYear W20042406932017 @default.
• W2004240693 countsByYear W20042406932018 @default.
• W2004240693 countsByYear W20042406932019 @default.
• W2004240693 countsByYear W20042406932020 @default.
• W2004240693 countsByYear W20042406932021 @default.
• W2004240693 countsByYear W20042406932022 @default.
• W2004240693 countsByYear W20042406932023 @default.
• W2004240693 crossrefType "journal-article" @default.
• W2004240693 hasAuthorship W2004240693A5000283880 @default.
• W2004240693 hasAuthorship W2004240693A5022654117 @default.
• W2004240693 hasAuthorship W2004240693A5025743822 @default.
• W2004240693 hasAuthorship W2004240693A5033082495 @default.
• W2004240693 hasAuthorship W2004240693A5038820719 @default.
• W2004240693 hasAuthorship W2004240693A5047058016 @default.
• W2004240693 hasAuthorship W2004240693A5073149554 @default.
• W2004240693 hasAuthorship W2004240693A5081226931 @default.
• W2004240693 hasAuthorship W2004240693A5091914061 @default.
• W2004240693 hasBestOaLocation W20042406931 @default.
• W2004240693 hasConcept C126322002 @default.
• W2004240693 hasConcept C142724271 @default.
• W2004240693 hasConcept C168563851 @default.
• W2004240693 hasConcept C197934379 @default.
• W2004240693 hasConcept C203014093 @default.
• W2004240693 hasConcept C204787440 @default.
• W2004240693 hasConcept C27081682 @default.
• W2004240693 hasConcept C2778375690 @default.
• W2004240693 hasConcept C2781069245 @default.
• W2004240693 hasConcept C71924100 @default.
• W2004240693 hasConceptScore W2004240693C126322002 @default.
• W2004240693 hasConceptScore W2004240693C142724271 @default.
• W2004240693 hasConceptScore W2004240693C168563851 @default.
• W2004240693 hasConceptScore W2004240693C197934379 @default.
• W2004240693 hasConceptScore W2004240693C203014093 @default.
• W2004240693 hasConceptScore W2004240693C204787440 @default.
• W2004240693 hasConceptScore W2004240693C27081682 @default.
• W2004240693 hasConceptScore W2004240693C2778375690 @default.
• W2004240693 hasConceptScore W2004240693C2781069245 @default.
• W2004240693 hasConceptScore W2004240693C71924100 @default.
• W2004240693 hasIssue "2" @default.
• W2004240693 hasLocation W20042406931 @default.
• W2004240693 hasLocation W20042406932 @default.
• W2004240693 hasLocation W20042406933 @default.
• W2004240693 hasLocation W20042406934 @default.
• W2004240693 hasLocation W20042406935 @default.
• W2004240693 hasOpenAccess W2004240693 @default.
• W2004240693 hasPrimaryLocation W20042406931 @default.
• W2004240693 hasRelatedWork W1990197915 @default.
• W2004240693 hasRelatedWork W2085830368 @default.
• W2004240693 hasRelatedWork W2087016115 @default.
• W2004240693 hasRelatedWork W2305775430 @default.
• W2004240693 hasRelatedWork W2349164817 @default.
• W2004240693 hasRelatedWork W2427186628 @default.
• W2004240693 hasRelatedWork W2465571689 @default.
• W2004240693 hasRelatedWork W3000123036 @default.
• W2004240693 hasRelatedWork W3191427281 @default.
• W2004240693 hasRelatedWork W4311628015 @default.

• next